

First-line dolutegravir/lamivudine in HIV-1 infection: lymph node penetration and reservoir decline in a randomized open-label clinical trial

Received: 4 May 2026

Accepted: 15 September 2026

Published online: 02 October 2026

 Check for updates

Elias P. Rosen¹, Stephen Bondoc², Lucía Bailón^{3,4,5}, Lidia Blay⁶, Albert Caballero⁶, Maria C. García-Guerrero⁷, Maria C. Puertas^{5,7,8}, Igor Moraes-Cardoso^{7,8,9}, Andrea Vazquez-Escobales^{3,4}, Julià Blanco^{5,7,8,10}, Beatriz Mothe^{3,4,5,7,8,10}, Angela DM Kashuba¹, Jacob D. Estes^{2,11}, Javier Martinez-Picado^{5,7,8,10,12,13}✉ & Jose Molto^{3,4,5,8,13}✉ On behalf of the DUALITY study group*

Dual antiretroviral therapy with dolutegravir and lamivudine (DTG/3TC) is a recommended first-line regimen for people with HIV, but whether reduced-drug therapy maintains adequate antiviral pressure within lymph node (LN) reservoirs remains uncertain. In the DUALITY clinical trial (EudraCT number 2019-002733-10), the prespecified primary endpoint—change in proviral HIV-1 DNA in peripheral blood CD4 + T cells from baseline to week 48—was similar between participants initiating DTG/3TC or dolutegravir-based triple therapy. Here, we investigated prespecified secondary endpoints comprising viral persistence and antiretroviral drug penetration and distribution in LN using multimodal imaging. In 39 participants undergoing inguinal LN excision at baseline or during the first year of treatment, HIV-1 DNA and RNA were detected by DNAscope/RNAscope and antiretroviral spatial distribution was mapped by mass spectrometry imaging. HIV-1-infected cells declined rapidly after treatment initiation across both treatment groups. Antiretrovirals were widely detected within LN tissue regions containing or adjacent to HIV-positive cells. These findings provide spatial evidence that DTG/3TC reaches LN tissue and HIV-positive cells, extending peripheral blood observations to a key anatomical HIV reservoir.

Dual antiretroviral therapy (ART) with dolutegravir and lamivudine (DTG/3TC) has demonstrated durable virologic suppression, favorable safety, and long-term effectiveness comparable to three-drug regimens in both clinical trials and real-world settings^{1–3}. On the basis of this evidence, DTG/3TC is now recommended as a preferred first-line ART option⁴. Despite its clinical success, questions remain regarding

the biological adequacy of dual therapy with DTG/3TC in anatomical compartments that harbor persistent HIV reservoirs.

The DUALITY clinical trial compared HIV-1 reservoir dynamics in ART-naïve people with HIV (PWH) initiating first-line ART with DTG/3TC (2DR) or a three-drug regimen consisting of dolutegravir plus emtricitabine/tenofovir alafenamide (DTG + FTC/TAF; 3DR). In

A full list of affiliations appears at the end of the paper. *A list of authors and their affiliations appears at the end of the paper.

✉ e-mail: jmpicado@irsicaixa.es; jmolto@lluaita.org

Table 1 | HIV-1 DNA- and RNA-positive cells in lymph nodes during the study

	vDNA+ cells/10 ⁵ cells				vRNA+ cells/10 ⁵ cells			
	DTG + 3TC		DTG + FTC/TAF		DTG + 3TC		DTG + FTC/TAF	
	N (n BLQ)	Median (min-max)	N (n BLQ)	Median (min-max)	N (n BLQ)	Median (min-max)	N (n BLQ)	Median (min-max)
Baseline (BL)	4 (0)	2.29 (0.80–4.14)	4 (0)	8.51 (0.51–36.86)	4 (0)	6.01 (1.37–13.03)	4 (0)	15.72 (0.62–38.41)
Week 2	4 (0)	0.43 (0.32–2.48)	4 (0)	2.39 (0.44–5.36)	4 (0)	1.07 (0.43–1.51)	4 (1)	0.61 (0.01–2.38)
Week 4	4 (0)	0.75 (0.26–1.48)	4 (0)	0.47 (0.15–1.27)	4 (1)	0.64 (BLQ–0.95)	4 (2)	0.07 (BLQ–0.19)
Week 12	4 (0)	0.29 (0.10–0.82)	3 (2)	BLQ (BLQ–0.83)	4 (2)	0.05 (BLQ–0.14)	3 (2)	BLQ (BLQ–0.12)
Week 48	3 (0)	0.33 (0.14–0.59)	4 (0)	0.45 (0.20–1.83)	3 (1)	0.28 (BLQ–1.46)	4 (3)	BLQ (BLQ–1.10)
Ratio week48/BL ^a		0.158 (0.036–0.416)		0.049 (0.002–0.532)		0.055 (0.007–0.692)		0.001 (< 0.01–0.009)

DTG dolutegravir, 3TC lamivudine, FTC emtricitabine, TAF tenofovir alafenamide, BLQ below lower limit of quantification.
^aExpressed as median (95% CI).

addition to comparable plasma viral suppression, the study demonstrated similar reductions in peripheral blood markers of HIV-1 reservoir, including total and intact HIV-1 DNA, cell-associated HIV-1 RNA, and the inducible reservoir⁵. However, peripheral blood measurements may not capture viral persistence within lymphoid tissues, particularly lymph nodes (LN), which are major contributors to the HIV reservoir^{6,7}.

Lymph nodes present structural and biological barriers to antiretroviral drug delivery. Their complex architecture, fibrosis, and heterogeneous microenvironment can limit drug penetration and create gradients in antiretroviral exposure^{8–11}. These features raise the possibility that reduced drug pressure under dual therapy with DTG/3TC could permit ongoing viral persistence in this sanctuary site, even when systemic viral suppression is achieved^{12,13}. Traditional approaches used to quantify viral burden or drug concentrations in lymphoid tissue, such as bulk PCR or liquid chromatography–mass spectrometry (LC-MS/MS), provide limited spatial information into these processes and therefore cannot resolve the relationship between infected cells, antiretroviral exposure, and tissue structure.

Recent advances in imaging technologies enable spatially resolved analysis of viral persistence and drug distribution within complex tissues. In situ hybridization (ISH), immunohistochemistry (IHC), and mass spectrometry imaging (MSI) allow visualization of infected cells and antiretroviral drugs within intact lymphoid architecture^{9,11,14}. Here, we applied a multimodal imaging strategy to characterize HIV persistence and antiretroviral drug distribution in LN during the first year of ART initiation in participants enrolled in the DUALITY clinical trial. By integrating in situ detection of viral nucleic acids with spatial mapping of antiretroviral drugs, we investigated tissue penetration and the spatial distribution of DTG/3TC within LN, while comparing LN reservoir dynamics between dual and triple therapy.

Here, we show that HIV-1 DNA- and RNA-positive cells in LN decline rapidly after initiation of either DTG/3TC or dolutegravir-based triple therapy and that DTG and 3TC are detectable within LN regions containing or adjacent to HIV-positive cells. By integrating in situ detection of viral nucleic acids with pharmacokinetic measurements and spatial drug mapping, we characterize antiretroviral penetration and HIV persistence within intact lymphoid tissue. These findings provide tissue-level evidence that DTG/3TC distributes within a key anatomical site of HIV persistence.

Results

Study population and safety

Forty participants in the DUALITY trial initially consented to undergo a single ultrasound-guided inguinal LN excision during the study. Biopsy timepoints were randomly assigned within each study arm, at baseline (pre-ART) or at weeks 2, 4, 12 or 48 after ART initiation, with four participants representing each arm per timepoint. One participant from the 2DR group declined the procedure and was not replaced; therefore, 39 participants were included in the final analysis. Baseline characteristics are summarized in Supplementary Table 1. The study population consisted of young men, with a median (IQR) plasma viral load of 23,828 (4921–50,045) copies/mL and CD4 + T cell count of 460 (364–568) cells/mm³ at study entry.

No severe complications were observed following LN excision. Mild seroma formation occurred in eight participants (20.5%), with the highest incidence observed early in the study (28.6%). This prompted a procedural review and implementation of a 48 h post-biopsy compressive bandage, and following this modification, seroma incidence declined to 11.1%.

HIV-1 DNA and RNA dynamics in lymph node

In situ hybridization analysis (ISH) of viral DNA (vDNA) and RNA (vRNA) was performed on subcutaneous LN sections using an adaptation of previously reported RNAscope protocols^{15,16}. Before ART initiation, HIV-1 DNA-positive (vDNA+) and RNA-positive (vRNA+) cells were detectable in all evaluable LN samples (Table 1). Baseline vDNA+ and vRNA+ cell counts were numerically higher in the 3DR group than in the 2DR group. At baseline, median (range) vDNA and vRNA levels were 2.29 (0.80–4.14) and 6.01 (0.62–38.41) positive cells/10⁵ cells in the 2DR group, and 8.51 (0.51–36.86) and 15.72 (0.62–38.41) positive cells/10⁵ cells in the 3DR group.

Following ART initiation both vDNA+ and vRNA+ cells in LN declined rapidly in both treatment groups (Fig. 1). Despite the numerically higher baseline values in the 3DR group, both regimens were associated with substantial reductions in LN vDNA+ and vRNA+ cells by week 48. The median fold change from baseline (95%CI) in vDNA+ cells was 0.158 (0.036–0.416) in the 2DR group and 0.055 (0.007–0.692) in the 3DR group. Corresponding fold changes in vRNA+ cells were 0.049 (0.002–0.532) and 0.001 (< 0.001–0.009), respectively (Table 1).




Fig. 1 | HIV-1 DNA- and RNA-positive cells in lymph nodes following anti-retroviral treatment initiation. **A** vDNA-positive cells and **B** vRNA-positive cells according to treatment group and sampling timepoint. Each dot represents one biologically independent participant sample, and lines represent medians. At baseline and weeks 2 and 4, $n = 4$ participants per treatment group; at week 12, $n = 4$

in the 2DR group and $n = 3$ in the 3DR group; and at week 48, $n = 3$ and $n = 4$, respectively. One lymph-node biopsy was obtained from each participant. vDNA +, HIV-1 DNA-positive; vRNA +, HIV-1 RNA-positive. Red indicates the two-drug regimen (2DR), and blue indicates the three-drug regimen (3DR).

Levels of vDNA+ cells in LN correlated with total and intact HIV-1 DNA in peripheral blood CD4+ T cells measured at the same timepoints (Spearman's $\rho = 0.55$, $p = 0.0005$; Spearman's $\rho = 0.67$, $p = 0.0039$, respectively; Fig. 2). Similarly, the level of LN vRNA+ cells also correlated with peripheral blood cell-associated HIV-1 RNA (Spearman's $\rho = 0.59$, $p = 0.0221$).

Quantitative analysis of antiretrovirals concentrations in plasma and lymph node

Venous blood sampling was performed in parallel to LN excision, and concentrations of antiretrovirals (tenofovir [TFV], FTC, 3TC, DTG) in plasma and in LN tissue homogenates along with the intracellular metabolites tenofovir diphosphate (TFVdp), emtricitabine triphosphate (FTCtp), and lamivudine triphosphate (3TCtp) were quantified using validated LC-MS/MS methods^{14,17,18}. Paired LN biopsies and plasma samples were collected ~24 h after dosing in 37 participants (median 26.7 h, min-max 19.5–32.0 h). Two participants sampled earlier post-dose were excluded from pharmacokinetic analyses, since drug concentrations were not representative of trough concentrations.

Antiretroviral concentrations in plasma and LN measured by LC-MS/MS, including parent drugs and phosphorylated active metabolites for nucleoside reverse transcriptase inhibitors (NRTI), are shown in Table 2. Plasma concentrations were consistent with previous reported 24 h trough measurements^{8,19–22}. Median (range) LN-to-plasma tissue penetration ratios (TPR) indicated preferential tissue accumulation of TFV (4.34 [2.06–11.62]), FTC (1.58 [0.24–5.20]), and 3TC (1.46 [0.02–6.46]), but not DTG (0.18 [0.05–0.37]). Despite its lower penetration ratio, DTG exhibited the highest absolute LN tissue concentrations (Table 2). Plasma and LN concentrations were strongly correlated for DTG (Spearman's $\rho = 0.819$, $p < 0.0001$), with weaker correlations for NRTI (Table 2, Supplementary Fig. 1). Notably, the tissue metabolite-to-parent ratio in LN was higher for 3TC (4.19 [0.58–9.16]) than for FTC (1.59 [0.57–5.73]) or TFV (1.58 [0.57–4.94]), suggesting more efficient phosphorylation to the active metabolite of 3TC in LN tissue (Table 2).

Spatial distribution of antiretrovirals in lymph node and colocalization with HIV-1 DNA- and RNA-positive cells

Spatial distribution of antiretrovirals within LN was assessed by Infrared Matrix-Assisted Laser Desorption Ionization (IR-MALDESI) Mass Spectrometry Imaging (MSI)^{9,11,23}. In MSI datasets, each measurement corresponds to a voxel (volumetric pixel), representing the three-dimensional tissue volume sampled by a single laser ablation

event. Although LC-MS/MS confirmed the presence of TFV in LN samples, TFV concentrations measured by MSI were below the lower limit of quantitation (LLOQ) and were therefore not detectable by this method. As a result, spatial analyses of antiretroviral distribution and colocalization with vDNA+ or vRNA+ cells focused on participants allocated to the 2DR group. Notably, because MSI LLOQ exceeded the reported in vitro IC₉₀ values for both DTG and 3TC^{19,24–28}, all locations in which DTG or 3TC were detected contained drug concentrations above these reference values.

DTG and 3TC were consistently detectable in LN tissue by MSI. Figure 3 displays representative spatial maps of DTG and 3TC for ID 295007 (2DR), collected at the week 2 timepoint. Total antiretroviral distributions are shown relative to CD20 expression of the LN B-cell follicles, from which it is evident that primary drug accumulation occurs within the extra-follicular T-cell zone or medulla. Drug distribution within LN tissue was heterogeneous, with median (range) relative standard deviations of 60% (36–77) for DTG and 43% (30–80) for 3TC. The proportion (median [range]) of LN tissue covered by at least one detectable antiretroviral was 65.3% (11.5–81.8), driven primarily by DTG (58.8% [1.1–79.9]). Notably, 32.0% (3.2–64.0) of LN tissue area was covered by combined detectable DTG and 3TC (Fig. 4A).

DTG and 3TC distributions were coregistered with vDNA+ and vRNA+ cells to assess their spatial relationship. This was done according to three different approaches (Fig. 4B): i) as the proportion of vDNA+ or vRNA+ cells with direct colocalization of drugs at the same voxel; ii) as the proportion of all neighboring voxels with detectable drug; and, iii) as the proportion of vDNA+ or vRNA+ cells with detectable drugs at any neighboring voxels. Representative colocalization between DTG and 3TC and vDNA+ and vRNA+ cells for ID 295007 at week 2 can be seen in Fig. 3, where antiretroviral distributions have been isolated in regions containing vDNA+ or vRNA+ cells and their nearest neighboring voxels to assess the spatial proximity of detectable drug signal. Colocalization results for DTG/3TC are summarized in Fig. 4C, D. Direct colocalization of DTG or 3TC with HIV-1 infected cells occurred in a median (range) of 45% (0–100) of vDNA+ cells and 50% (0–100) of vRNA+ cells, and, as with total tissue coverage, this was largely driven by DTG. When considering the proportion of sampling locations adjacent to infected cells with detectable antiretroviral drug, colocalization percentages were 60% (11–100) for vDNA+ cells and 44% (0–72) for vRNA+ cells. Notably, 100% (50–100) of vDNA+ cells and 100% (0–100) of vRNA+ cells had at least one neighboring voxel containing DTG or 3TC.




Fig. 2 | Correlations between HIV-1 reservoir measurements in peripheral blood CD4+ T cells and in lymph nodes. **A** Total HIV-1 DNA ($n = 36$ participants), **B** Intact HIV-1 DNA ($n = 17$ participants), **C** Cell-associated HIV-1 RNA ($n = 15$ participants). Associations were assessed using two-sided Spearman rank correlation tests. Spearman's ρ and exact p values are shown. No adjustment for multiple

comparisons was applied because the analyses were exploratory. Each point represents paired measurements from one biologically independent participant. vDNA+, HIV-1 DNA-positive; vRNA+, HIV-1 RNA-positive; ca-RNA, cell-associated HIV-1 RNA; TBP, TATA-binding protein. Colours indicate the sampling timepoint, as defined in the figure.

Collagen deposition and antiretroviral drugs penetration in lymph node

Collagen deposition was measured in LN by IHC, as a marker of LN fibrosis. Overall, collagen I occupied a median (range) of 9% (2–19) of LN tissue area and did not show consistent temporal changes following ART initiation in either treatment group. Collagen deposition was not associated with clinical parameters or peripheral blood reservoir measures (Supplementary Fig. 2).

Representative colocalization of collagen I and DTG or 3TC can be seen in Fig. 3. Quantitative imaging analysis from individuals allocated to the 2DR group found that colocalization between antiretrovirals and collagen (median [range] of 49% [9–77]) was lower than the total antiretroviral tissue coverage and that the majority of collagen colocalization occurred with DTG (45% [1–76]). Notably, greater collagen deposition in the LN was associated with lower DTG LN-to-plasma ratios, reduced tissue concentrations of DTG, and diminished antiretroviral coverage of LN tissue and HIV-infected cells (Supplementary Fig. 3), although these relationships did not reach statistical significance.

Discussion

In this sub-study of the DUALITY clinical trial, we provide an integrated spatial assessment of HIV-1 persistence and antiretroviral drug penetration in human LN during initiation of first-line ART with DTG/3TC. Using a multimodal approach combining ISH, MSI, and tissue pharmacokinetics, we show that HIV-infected cells within LN decline rapidly after ART initiation following either DTG/3TC or DTG-based triple-

drug therapy. These findings extend our prior observations in peripheral blood and provide direct tissue-level evidence addressing concerns that dual ART with DTG/3TC may exert insufficient antiviral pressure within anatomical reservoir sites.

The rapid decline in vRNA+ and vDNA+ cells observed in LN mirrored the early reductions detected in peripheral CD4+ T cells^{5,29}, consistent with potent antiviral activity across compartments enriched for long-lived infected cells. As described in prior HIV and SIV studies^{30–33}, vRNA declined more rapidly than vDNA, consistent with preferential clearance of transcriptionally active infected cells. By week 48, both regimens were associated with substantial declines in LN HIV-1 DNA and RNA, consistent with our previous observations in peripheral blood, and reservoir levels in LN were of a similar order of magnitude in both treatment arms. Notably, although fold-change estimates showed marked reductions in both groups, the numerically larger reductions observed in the 3DR arm should be interpreted cautiously given the baseline differences between treatment arms and the very limited sample size. Consequently, this exploratory substudy was not designed to establish superiority or equivalence between regimens. Nevertheless, our findings suggest that DTG/3TC provides sufficient drug pressure to limit viral persistence in lymphoid tissues.

Our findings also have implications for the use of LN biopsies to study HIV reservoir dynamics. Lymph node sampling is an invasive procedure that requires surgical expertise and may be associated with complications such as seroma formation, bleeding, or infection. In this study, measures of HIV-1 persistence in LN correlated with corresponding determinations in peripheral blood CD4+ T cells, including

Table 2 | Antiretroviral drug concentrations in plasma and lymph nodes, measured by LC-MS/MS

	<i>N</i>	Plasma	Lymph Node		LN/ Plasma Ratio	LN:Plasma Correlation	LN Metabolite/ Parent Ratio	LN Metabolite: Parent drug Correlation Spearman's ρ , (<i>p</i> -value)	Reference value
		ng/mL	μg/g	fmol/ 10 ⁶ cells					
DTG	29	1290 (620–3240)	0.261 (0.072–0.739)		0.18 (0.05–0.37)	0.819 (< 0.0001)			64 ^{*28}
3TC	14	47.1 (31.1–88.9)	0.078 (0.001–0.286)		1.46 (0.02–6.46)	–0.08, (0.782)			
3TCtp			0.839 (0.008–1.886)	527 (5–1251)			4.19 (0.58–9.16)	0.688 (0.013)	564 ^{**24,25}
FTC	15	58.7 (40.0–150.0)	0.114 (0.012–0.368)		1.58 (0.24–5.20)	0.278 (0.336)			
FTCtp			0.342 (0.026–1.652)	258 (15–990)			1.59 (0.57–5.73)	0.366 (0.198)	338 ^{**38}
TFV	15	9.8 (4.4–14.2)	0.044 (0.022–0.108)		4.34 (2.06–11.62)	0.277 (0.340)			
TFVdp			0.145 (0.049–0.550)	104 (35–395)			1.58 (0.57–4.94)	0.516 (0.059)	51 ^{***38}

Associations were assessed using two-sided Spearman rank correlation tests. No adjustment for multiple comparisons was applied because the analyses were exploratory. Correlation coefficients are reported as Spearman's ρ with exact *p* values. *N* represents the number of biologically independent participants included in each analysis. Data are expressed as median (min-max); *IC90 (ng/mL); **IC50 (fmol/10⁶ cells); ***EC50 (fmol/10⁶ cells).
LN lymph node, DTG dolutegravir, 3TC lamivudine, 3TCtp lamivudine triphosphate, FTC emtricitabine, FTCtp emtricitabine triphosphate, TFV tenofovir, TFVdp tenofovir diphosphate.




Fig. 3 | Representative spatial colocalization of HIV-1 vDNA- and vRNA-positive cells with antiretroviral drugs in lymph nodes (ID 295007, week 2). Representative spatial maps from participant ID 295007 at week 2 show CD20 + B cells, vDNA+ cells, vRNA+ cells and collagen I alongside the corresponding distributions of 3TC, DTG and their overlay. In the overlay, green indicates 3TC, red indicates DTG and yellow indicates detection of both drugs. Scale bar, 1 mm; the same scale applies to all panels. vDNA + , HIV-1 DNA-positive; vRNA + , HIV-1 RNA-positive; DTG, dolutegravir; 3TC, lamivudine.




Fig. 4 | Lymph node antiretroviral distribution and spatial proximity to HIV-1 positive cells. **A** Antiretroviral coverage of lymph node tissue. **B** Approaches used to assess the spatial distribution of antiretroviral drugs relative to HIV-1-positive cells. Colocalization of antiretroviral drugs with vDNA-positive (**C**) and vRNA-positive (**D**) cells in participants allocated to the 2DR group. Each dot represents one participant and lines indicate medians. Data were derived from biologically independent lymph-node samples, with one biopsy obtained from each

participant. In (**A**), $n = 14$ participants with evaluable mass spectrometry imaging data; in (**C**), $n = 14$ participants with evaluable vDNA+ cells; and in (**D**), $n = 11$ participants with evaluable vRNA+ cells. No technical replicates are presented as independent observations. Green indicates 3TC, blue indicates DTG and purple indicates either DTG or 3TC. ARV, antiretroviral; vDNA +, HIV-1 DNA-positive; vRNA +, HIV-1 RNA-positive; DTG, dolutegravir; 3TC, lamivudine.

total and intact HIV-1 DNA and cell-associated HIV-1 RNA. These observations suggest that peripheral blood measurements may partly reflect reservoir dynamics occurring within lymphoid tissues. Although LN remain a key anatomical site of HIV persistence and provide spatial insights that cannot be captured in blood, our results indicate that blood-based reservoir measurements may provide a useful surrogate for assessing global reservoir dynamics in clinical studies.

The biological adequacy of DTG/3TC within LN is further supported by our pharmacokinetic analyses. LC-MS/MS of LN tissue homogenates, reflecting an average concentration within each sample, confirmed that all drugs and their active metabolites reached the LN compartment at concentrations generally near or exceeding reported *in vitro* inhibitory reference values^{19,34,35}, with DTG achieving the highest absolute concentrations despite lower LN-to-plasma ratios, likely reflecting its high degree of plasma protein binding. Consistent with previous work^{9,11}, MSI revealed substantial spatial heterogeneity in the distribution of DTG and 3TC within cross-sections of LN tissue, indicating the presence of local gradients in total drug exposure. Nevertheless, DTG was present in approximately 60% of LN tissue, with combined DTG and 3TC coverage in one-third of the tissue area. Consistent with its higher lipophilicity, DTG was the primary driver of tissue and target-cell exposure.

Importantly, despite heterogeneous drug distribution, nearly all infected cells were located within regions containing detectable antiretroviral signal corresponding to parent drug concentrations above the reported *in vitro* IC₉₀ values in their immediate microenvironment. Although direct colocalization occurred in only 40–60% of infected cells, almost all vDNA+ and vRNA+ cells had at least one

neighboring voxel containing DTG or 3TC. While rapid degradation of phosphorylated metabolites in thawed tissue sections precludes their measurement by MSI, it is anticipated that spatial distribution of 3TCtp may be similar to that of 3TC. Given that CD4+ T cells are highly motile in LN, infected cells are likely migrating in and out of regions of high ARV exposure. These spatial findings indicate that DTG/3TC were detectable within regions containing HIV-infected cells, supporting biologically plausible antiviral exposure within lymphoid tissue. However, the present study was not designed to determine the contribution of individual drugs or establish a causal relationship between local drug distribution and reservoir decay. Compared with prior MSI studies in non-human primates using 4-drug ART regimens^{9,11}, our results show that DTG/3TC achieves equal or greater proximity to infected cells, likely reflecting favorable physicochemical properties and preferential distribution within extra-follicular T-cell zones, where most HIV-infected cells reside.

We also evaluated collagen I expression as a marker of LN fibrosis^{36,37}. Overall, collagen deposition was modest, stable over time, and comparable across participants. While no correlation was observed between collagen content and NRTI tissue concentrations, greater collagen deposition tended to correlate with lower DTG penetration and diminished ARV coverage of infected cells. Although these relationships did not reach statistical significance, likely reflecting limited sample size, their directionality is consistent with the hypothesis that fibrosis may restrict diffusion of certain antiretroviral drugs within lymphoid tissue.

This study is strengthened by its integrated, multimodal imaging approach, which enables simultaneous assessment of viral persistence, drug exposure, and tissue architecture within human LN during ART

initiation. The collection of LN samples at multiple early timepoints enables characterization of reservoir decay at the tissue level. These data are relevant given the prevalence of infected cells within the LN and its potential role as a conduit for rapid viral rebound following treatment interruption. Therefore, these findings have implications not only for ART durability but also for strategies targeting tissue reservoirs in HIV remission and cure research. This study longitudinally integrates spatial antiretroviral drug imaging with measurements of the HIV reservoir in human LN during the first year of ART, thereby extending previous observations derived from peripheral blood analyses.

Several limitations should also be considered. First, each participant contributed a single LN biopsy, preventing longitudinal within-subject analysis and limiting the ability to account for inter-individual variability. Second, the relatively small sample size restricted the power to evaluate correlations. Although the number of participants per time point was limited, this sampling design reflects the ethical and logistical constraints of LN excision studies in humans. Despite modest sample size, the consistency across virologic, pharmacokinetic, and spatial analyses supports the robustness of our findings. Finally, MSI lacked sensitivity for TFV, limiting spatial analyses in the 3DR arm. The volume of material probed by IR-MALDESI at each sampling location across a tissue section is inherently much smaller than an LC-MS/MS tissue homogenate to preserve discrete spatial information, and there is a commensurate difference in analyte sensitivity. Because TFV concentrations were below the MSI LLOQ, the complete spatial distribution of the triple-drug regimen could not be reconstructed. Consequently, direct spatial comparison between the complete dual- and triple-drug regimens was not possible. Accordingly, spatial analyses were restricted to the 2DR arm, as comparison with DTG/FTC alone would not represent the complete 3DR regimen and could therefore mislead interpretation.

In conclusion, this study provides direct human tissue-level evidence that dual ART with DTG/3TC achieves antiretroviral exposure within LN and is associated with a rapid decline in HIV-infected cells during the first year of therapy. While the clinical efficacy of DTG/3TC has been established in randomized clinical trials, these findings extend previous peripheral blood observations by linking pharmacokinetic and virological measurements within lymphoid tissue. Together, these results provide biological evidence of antiviral activity, antiretroviral distribution, and HIV reservoir decline within a key anatomical site of viral persistence, complementing the established clinical efficacy of DTG/3TC.

Methods

Study design and objectives

DUALITY was a randomized, open-label clinical trial conducted in 44 ART-naïve PWH at the Infectious Diseases Department of Hospital Universitari Germans Trias i Pujol (Badalona, Spain). Participants were randomized (1:1) to initiate first-line ART with once-daily dolutegravir (DTG) 50 mg plus lamivudine (3TC) 300 mg (2DR group) or DTG 50 mg plus emtricitabine/tenofovir alafenamide 200/25 mg (DTG + FTC/TAF; 3DR group) and were followed for 48 weeks. Randomization was stratified according to whether the estimated time since HIV acquisition was <3 or ≥3 months and whether screening plasma HIV-1 RNA was <100,000 or ≥100,000 copies/mL. The prespecified primary endpoint was the change in proviral HIV-1 DNA in peripheral blood CD4⁺ T cells from baseline to week 48 and has been reported previously⁵. The prespecified secondary endpoints evaluated in this substudy were HIV-1 reservoir dynamics within peripheral LN during the first year of ART, and antiretroviral pharmacokinetics and spatial drug distribution in relation to viral expression within LN tissue.

Lymph node and blood sampling

For these objectives, 40 participants in the DUALITY study (20 per treatment arm) were invited to undergo a single inguinal LN excision during follow-up. Biopsy timepoints were randomly assigned within each arm at baseline (pre-ART) or at weeks 2, 4, 12 or 48 after ART initiation, with four participants per arm per timepoint. Venous blood sampling was performed in parallel to LN excision, ~24 h after dosing. LNs were identified by ultrasound, and biopsies were conducted by experienced surgeons under local anesthesia using standard sterile techniques. A single LN was removed through a 1–2 cm skin incision, snap-frozen, and stored at –80 °C together with plasma samples until analysis.

Tissue sectioning

Each flash-frozen LN sample was adhered to a specimen disc with O.C.T. (Tissue-Tek; Sakura Finetek, Inc., Torrance, CA) and sectioned at –20 °C using a Leica CMI950 cryomicrotome (Leica Biosystems, Buffalo Grove, IL). Subjacent LN sections (10 µm) from each sample were thaw-mounted onto positively charged glass slides (IHC and ISH; *n* = 10) or plain glass slides (IR-MALDESI; *n* = 3). LN tissue from one participant (3DR, week 12) was damaged during cryosectioning and excluded from HIV DNA and RNA imaging but retained for drug distribution analyses.

RNAscope/DNAscope ISH and multiplex IHC

ISH analysis of viral vRNA and vDNA was performed on subjacent LN sections using an adaptation of previously reported RNAscope protocols^{15,16}. Specifically, frozen tissues mounted on slides were thawed and dried at room temperature for 15 min and then dipped in phosphate-buffered saline (PBS) for 10 s prior to fixation. Slides were fixed by incubating in 4% paraformaldehyde (PFA) fixative (catalog number 15714-S; Electron Microscopy Sciences) in PBS for 2 h at room temperature followed by two 5 min incubations of 100% ethanol and then two rinses of double-distilled water (ddH₂O). Heat-induced epitope retrieval was performed as follows: Slides were submerged in 1x RNAscope Target Retrieval Reagent (catalog number 322000; ACD) preheated to 97 °C and then incubated and held at constant temperature for 5 min, and then immediately transferred to PBS. Slides were then incubated in peroxidase blocking solution (3% H₂O₂ diluted in 1x PBS) for 10 min at room temperature, followed by a ddH₂O rinse.

Slides were incubated with clade specific target probes for HIV RNA or HIV DNA (Catalog numbers 416101, 416111, 429841, 446551, 426341, 425531, 430171, 478191; ACD) for 2 h at 40 °C. Amplification was performed using the RNAscope 2.5 red detection kit (catalog number 322360; ACD) using 0.5x wash buffer (catalog number 310091; ACD) for all washing steps. Slides were developed using Warp Red (catalog number WR806; Biocare) for 2 min.

Slides were then stained at room temperature using mouse anti-Collagen I (catalog number C2456; Sigma) (4.0 mg/mL) at 1:200 and goat anti-CD20 (catalog number PA1-9024; Invitrogen) (0.5 mg/mL) at 1:200 overnight. The slides were then incubated with fluorescent secondaries donkey anti-mouse-AF647 (catalog number A31571; Invitrogen) (2 mg/mL) at 1:300 and donkey anti-goat-AF488 (catalog number A11055; Invitrogen) (2 mg/mL) at 1:200 for 1 h. Slides were counterstained with 4',6-diamidino-2-phenylindole (DAPI) (catalog number D1306; Invitrogen) at a dilution of 0.5 µg/mL in ddH₂O for 10 min and coverslipped using Prolong Gold antifade mounting medium (catalog number P36930; ThermoFisher), and whole tissues were imaged on an AxioScan.Z1 instrument (Zeiss) using a Plan Apochromat 20× objective (0.8 numerical aperture [NA], FWD = 0.55 mm; Zeiss). After fluorescent imaging, coverslips were removed and slides were counterstained with CAT hematoxylin (catalog number CATHE-GL;

Biocare), mounted in Permount (Catalog number SP15-100; Fisher Scientific), and reimaged at 40x magnification on a brightfield Apero AT2 (Leica Biosystems).

Manual annotations were drawn to define tissue regions and exclude areas of high artifact or morphological disruption from cryo-sectioning. HIV-infected cells were detected using the Object Colocalization v2.1.5 module within HALO image analysis software (v4.0; Indica Labs) using a minimum size threshold of 4.0 μm^2 for RNA puncta and 0.5 μm^2 for DNA puncta. Cell segmentation was performed using the Cytonuclear v1.6 module (v4.0; Indica Labs) to determine cellular density. Annotation pins were placed on putative HIV-infected cells based on anatomic localization and cell morphology. The fluorescent property of the Warp Red chromogen ensured that annotation pin identifiers matched cell-to-cell between brightfield and fluorescent images. Manual annotations based on CD20 staining were used to delineate the positions of B-cell follicles.

LC-MS/MS and IR-MALDESI MSI analysis of antiretroviral drugs

Validated LC-MS/MS methods were used to quantify concentrations of TFV, FTC, 3TC, DTG in plasma and in snap-frozen LN tissue homogenized following sectioning, as well as to quantify intracellular metabolites TFVdp, FTCtp, and 3TCtp in LN homogenates^{14,17,18}. TFV was monitored in plasma and tissue rather than TAF due to its longer half-life. Samples were extracted by protein precipitation with isotopically-labeled internal standards. Extracts were analyzed by a Shimadzu high-performance liquid chromatography system with analyte detection by a SCIEX API 5000 mass spectrometer. The lower limit of quantitation (LLOQ) in plasma was 1 ng/mL for all antiretrovirals. The LLOQs in tissue homogenates were 0.1 ng/mL (TFV, FTC, 3TC, and DTG) and 0.2 ng/mL (TFVdp, FTCtp, 3TCtp). Sample concentrations were converted to units of ng/g or fmol/g for final reporting using the mass of tissue analyzed and the volume of the homogenization solvent. Assay precision and accuracy were within 15%. IF cell counts associated with each sample were used as estimates of tissue cell density for scaling intracellular metabolite concentrations to units of fmol/ 10^6 cells for purposes of comparison to other studies.

Spatial distribution of antiretrovirals within LN was assessed by IR-MALDESI MSI^{9,11,23}. The technique utilizes an infrared laser to volatilize material from a focused region (a $100 \times 100 \times 10 \mu\text{m}$

³ voxel), which is subsequently ionized by an electrospray before chemical analysis by a Thermo Fisher Scientific Q Exactive mass spectrometer (Bremen, Germany). Antiretroviral quantification by IR-MALDESI was determined by spotting calibration standards of known drug concentration onto LN tissue collected from individuals at week 0 prior to ART initiation. Intracellular metabolites could not be quantified by IR-MALDESI due to their degradation during sectioning¹⁴. Per-voxel limits of detection were assessed based on the standard deviation of each analyte from replicate measurements of drug concentrations spotted onto blank tissue samples, and the slope of the calibration curve, with a signal-to-noise ratio of 3. Estimated IR-MALDESI LLOQs were 440 ng/g (TFV), 620 ng/g (FTC), 490 ng/g (3TC), and 240 ng/g (DTG).

Image co-registration and colocalization analysis

Co-registration of MSI, ISH, and IHC images was performed in Matlab R2024a. Imported IF image data was color thresholded to isolate Collagen I staining, and then all image data and manual annotations of cell-associated vRNA and vDNA were down-sampled to match the spatial resolution of MSI data (pixel size: $100 \times 100 \mu\text{m}$) using the Image Processing Toolbox as described elsewhere^{9,11,23}. All image alignment was performed by manual selection of control points common to paired images of IF CD20 expression and an MSI endogenous lipid upregulated in B-cell follicles¹¹, followed by rigid

registration (Supplementary Fig. 4). Colocalization analysis was constrained to tissue regions where ISH and IHC staining was successful. Spatial distributions of vRNA, vDNA, CD20, and collagen I were used to create binary masks associated with each marker, and additional masks of vRNA and vDNA were created that included all nearest-neighboring voxels to each location of vRNA+ and vDNA+ cells. These masks were applied to MSI antiretroviral distributions to isolate the exposure of drug to each discrete target. To ensure that only drug exposure from parenchymal tissue was evaluated, spatial MSI antiretroviral response was corrected in regions there was colocalization with the blood marker heme.

Statistical analysis

Given that LN biopsy is an invasive procedure, each participant contributed a single LN biopsy; thus, data represent independent samples at each timepoint. Given these sampling constraints, we employed a naive pooled data analysis approach to describe changes in LN HIV-1 reservoir size over time. This approach allows comparison of distributions and trends across time points and treatment groups, under the assumption that biopsies at each time point are independent observations. Fold changes in HIV-1 DNA and RNA at week 48 relative to baseline were calculated as ratios of medians with 95% confidence intervals (95% CI) derived by nonparametric bias-corrected and accelerated (BCa) bootstrap resampling (1000 iterations). For ratio calculations and graphical purposes, values below the LLOQ were set at 0.01 copies/ 10^5 cells. Given the exploratory nature of this analysis and the limited sample size, no formal hypothesis testing between 2DR and 3DR arms was performed. Correlations between various HIV-1 reservoir measures and pharmacokinetic parameters in LN and peripheral blood were assessed using Spearman's rank correlation with pooled data from all participants. All reported correlation tests were two-sided, and no adjustment for multiple comparisons was applied because the analyses were exploratory. The analysis was carried out using R project version 4.5.2. For graphical representations, GraphPad Prism version 11.0.0 was used.

Ethics statement

All participants provided written informed consent. The study was approved by the institutional ethical review board (reference number AC-19-073-HGT-CEIM) and by the Spanish Regulatory Authorities and was conducted in accordance with the principles of the Helsinki Declaration and local personal data protection law (LOPD 15/1999). The study was registered at <https://www.clinicaltrialsregister.eu> (EudraCT number 2019-002733-10).

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

Individual-level clinical, virological, pharmacokinetic and tissue-imaging data are not publicly available because the small clinical cohort creates a potential risk of participant reidentification. Deidentified data may be made available to qualified researchers for scientifically and ethically appropriate research that is consistent with the study objectives and applicable data-protection requirements. Requests should be submitted to the corresponding author, and should include a research proposal, analysis plan, requested variables and information about the requesting investigators and institution. Requests will be reviewed by the DUALITY study investigators and the relevant institutional bodies. Access will require approval of the proposal and execution of a data-use agreement that prohibits participant

reidentification and unauthorized data sharing. The study protocol is provided in the Supplementary Information.

References

- Patel, R. et al. HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review. *Infect. Dis. Ther.* **10**, 2051–2070 (2021).
- Cahn, P. et al. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection. *AIDS* **36**, 39–48 (2022).
- Vergori, A. et al. Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort. *J. Antimicrob. Chemother.* **80**, 3082–3091 (2025).
- Ambrosioni, J. et al. Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025. *HIV Med.* <https://doi.org/10.1111/hiv.70120>. (2025).
- Bailón, L. et al. Impact of dolutegravir plus lamivudine as first-line antiretroviral treatment on the human immunodeficiency virus type 1 reservoir and inflammatory markers in peripheral blood. *J. Infect. Dis.* **231**, 600–610 (2025).
- Scholz, E. M. B. & Kashuba, A. D. M. The lymph node reservoir: physiology, HIV infection, and antiretroviral therapy. *Clin. Pharm. Ther.* **109**, 918–927 (2021).
- Banga, R. et al. Lymph node dendritic cells harbor inducible replication-competent HIV despite years of suppressive ART. *Cell Host Microbe* **31**, 1714–1731.e9 (2023).
- Fletcher, C. V. et al. The lymphoid tissue pharmacokinetics of tenofovir disoproxil fumarate and tenofovir alafenamide in HIV-infected persons. *Clin. Pharm. Ther.* **108**, 971–975 (2020).
- Scholz, E. M. B. et al. Quantitative imaging analysis of the spatial relationship between antiretrovirals, reverse transcriptase simian-human immunodeficiency virus RNA, and collagen in the mesenteric lymph nodes of nonhuman primates. *Antimicrob. Agents Chemother.* **65**, e00019–e00021 (2021).
- Kalada, W. & Cory, T. J. The importance of tissue sanctuaries and cellular reservoirs of HIV-1. *Curr. HIV Res.* **20**, 102–110 (2022).
- Rosen, E. P. et al. Antiretroviral drug exposure in lymph nodes is heterogeneous and drug dependent. *J. Int AIDS Soc.* **25**, e25895 (2022).
- Fletcher, C. V. et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. *Proc. Natl. Acad. Sci. USA* **111**, 2307–2312 (2014).
- Fletcher, C. V. et al. Persistent HIV transcription and variable ARV penetration in lymph nodes during plasma viral suppression. *AIDS* **36**, 985–990 (2022).
- Thompson, C. G. et al. Mass spectrometry imaging reveals heterogeneous efavirenz distribution within putative HIV reservoirs. *Antimicrob. Agents Chemother.* **59**, 2944–2948 (2015).
- Deleage, C. et al. Defining HIV and SIV reservoirs in lymphoid tissues. *Pathog. Immun.* **1**, 68–106 (2016).
- Devanathan, A. S. et al. Quantitative imaging analysis of the spatial relationship between antiretrovirals, reverse transcriptase simian-human immunodeficiency virus RNA, and fibrosis in the spleens of nonhuman primates. *Antimicrob. Agents Chemother.* **66**, e0060922 (2022).
- Weber, M. D. et al. Virological and immunological responses to raltegravir and dolutegravir in the gut-associated lymphoid tissue of HIV-infected men and women. *Antivir. Ther.* **23**, 495–504 (2018).
- Burgunder, E. et al. Antiretroviral drug concentrations in lymph nodes: a cross-species comparison of the effect of drug transporter expression, viral infection, and sex in humanized mice, nonhuman primates, and humans. *J. Pharm. Exp. Ther.* **370**, 360–368 (2019).
- Yuen, G. J. et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. *Antimicrob. Agents Chemother.* **48**, 176–182 (2004).
- Min, S. et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. *AIDS* **25**, 1737–1745 (2011).
- Min, S. et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. *Antimicrob. Agents Chemother.* **54**, 254–258 (2010).
- Thurman, A. R. et al. Safety and pharmacokinetics of a tenofovir alafenamide fumarate-emtricitabine based oral antiretroviral regimen for prevention of HIV acquisition in women: a randomized controlled trial. *EClinicalMedicine* **36**, 100893 (2021).
- Bokhart, M. T. et al. Quantitative mass spectrometry imaging of emtricitabine in cervical tissue model using infrared matrix-assisted laser desorption electrospray ionization. *Anal. Bioanal. Chem.* **407**, 2073–2084 (2015).
- Dumond, J. B. et al. Pharmacokinetic modeling of lamivudine and zidovudine triphosphates predicts differential pharmacokinetics in seminal mononuclear cells and peripheral blood mononuclear cells. *Antimicrob. Agents Chemother.* **59**, 6395–6401 (2015).
- Duan, C. et al. Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates. *J. Infect. Dis.* **184**, 1336–1340 (2001).
- Else, L. J. et al. Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing. *J. Antimicrob. Chemother.* **79**, 1597–1605 (2024).
- Else, L. et al. Pre-clinical evaluation of tenofovir and tenofovir alafenamide for HIV-1 pre-exposure prophylaxis in foreskin tissue. *Pharmaceutics* **14**, 1285 (2022).
- Cottrell, M. L., Hadzic, T. & Kashuba, A. D. M. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. *Clin. Pharmacokinet.* **52**, 981–994 (2013).
- Puertas, M. C. et al. Rapid clearance of inducible HIV-1 proviruses after initiation of antiretroviral therapy. *PLoS Pathog.* **21**, e1013466 (2025).
- Pasternak, A. O., Lukashov, V. V. & Berkhout, B. Cell-associated HIV RNA: a dynamic biomarker of viral persistence. *Retrovirology* **10**, 41 (2013).
- Scherpenisse, M., Kootstra, N. A., Bakker, M., Berkhout, B. & Pasternak, A. O. Cell-associated HIV-1 unspliced-to-multiply-spliced RNA ratio at 12 weeks of ART predicts immune reconstitution on therapy. *mBio* **12**, e00099–21 (2021).
- Ziani, W. et al. Increased proviral DNA in circulating cells correlates with plasma viral rebound in Simian immunodeficiency virus-infected rhesus macaques after antiretroviral therapy interruption. *J. Virol.* **95**, e02064–20 (2021).
- King, I. V. et al. Origin and Correlates of Viral Rebound in SIV-Infected Rhesus Macaques Following ART Discontinuation. *bioRxiv* 2025.08.30.673277 <https://doi.org/10.1101/2025.08.30.673277> (2025).
- Emtriva Prescribing Information: https://www.ema.europa.eu/en/documents/product-information/emtriva-epar-product-information_en.pdf.
- Kobayashi, M. et al. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. *Antimicrob. Agents Chemother.* **55**, 813–821 (2011).
- Deleage, C., Turkbey, B. & Estes, J. D. Imaging lymphoid tissues in nonhuman primates to understand SIV pathogenesis and persistence. *Curr. Opin. Virol.* **19**, 77–84 (2016).

37. Lederman, M. M. & Margolis, L. The lymph node in HIV pathogenesis. *Semin Immunol.* **20**, 187–195 (2008).
38. Cottrell, M. L. et al. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. *J. Infect. Dis.* **214**, 55–64 (2016).

Acknowledgements

Our sincere gratitude to all the volunteers participating in this study for their perseverance and dedication. ChatGPT (OpenAI) was used for assistance with grammar and language refinement only. It did not contribute to the scientific content, data interpretation, or writing of the manuscript. All final content and interpretations are the responsibility of the authors. Fundació Lluita contra les Infeccions acted as the study sponsor and was responsible for trial oversight and coordination. Study design, data collection, data analysis, data interpretation and manuscript preparation were undertaken by the academic investigator team, which included investigators affiliated with the sponsor. The external funders reviewed the manuscript for factual accuracy but had no role in study design, data collection, data analysis, data interpretation or manuscript writing. ViiV Healthcare reviewed the manuscript for factual accuracy before submission.

Author contributions

E.P.R.: MSI analysis, data review and editing; S.B.: ISH, IHC analysis, review and editing; L.B.: clinical trial execution, original draft preparation; L.B.L.: LN biopsies, review and editing; A.C.: LN biopsies, review and editing; M.C.G.: HIV-1 reservoir determinations, review and editing; M.C.P.: HIV-1 reservoir determinations, review and editing; I.M.C.: immune activation and exhaustion markers determinations, review and editing; A.V.: original draft preparation; J.B.: inflammatory biomarkers determinations, review and editing; B.M.: clinical trial execution, review and editing; A.D.M.K.: data review and editing; J.D.E.: data review and editing; J.M.P.: conceptualization, supervision, review and editing; J.M.: conceptualization, clinical trial execution, supervision, original draft preparation.

Funding

This work was funded by ViiV Healthcare (ISS #213096), the National Institutes of Health/National Institute of Allergy and Infectious Diseases (UM1 A1164561 and R01 A1143411), and Fundació Lluita Contra les Infeccions. IMC has the financial support of the predoctoral program AGAUR-FI ajuts (2023 FI-1 00326), Joan Oró of the Secretariat of Universities and Research of the Department of Research and Universities of the Generalitat of Catalonia and the European Social Plus Fund.

Competing interests

M.C.P. has received institutional research funding from Gilead Sciences. J.B. has received institutional research funding from MSD, HIPRA, has been CEO and founder of ALbaJuna Therapeutics, and has served as consultant for NESAPOR and HIPRA. BM reports consultancy personal

fees from AELIX Therapeutics SL, MSD and AbbVie, as well as speakers' fees from Gilead, Janssen, HIPRA and ViiV Healthcare, outside the submitted work. J.M.P. has received research funding, consultancy fees and lecture sponsorships from and has served on advisory boards for various laboratories (MSD, Gilead Sciences, ViiV Healthcare). J.M. has received research funding, consultancy fees and lecture sponsorships from and has served on advisory boards for various laboratories (MSD, Gilead Sciences, ViiV Healthcare, Johnson & Johnson). All other authors report no potential conflicts.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41467-026-78190-9>.

Correspondence and requests for materials should be addressed to Javier Martinez-Picado or Jose Molto.

Peer review information *Nature Communications* thanks Courtney Fletcher and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2026

This Article in Press is shared early to give you faster access to new research. It is citable and carries a permanent DOI. The final edited version will replace it automatically.

¹Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ²Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, OR, USA. ³Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. ⁴Fundació Lluita contra les Infeccions, Badalona, Spain. ⁵CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain. ⁶Department of General Surgery, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. ⁷IrsiCaixa, Badalona, Barcelona, Spain. ⁸Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain. ⁹Autonomous University of Barcelona, Cerdanyola del Vallés, Barcelona, Spain. ¹⁰University of Vic-Central University of Catalonia (UVic-UCC), Vic, Spain. ¹¹Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA. ¹²Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain. ¹³These authors jointly supervised this work: Javier Martinez-Picado, Jose Molto.

✉ e-mail: jmpicado@irsicaixa.es; jmolto@lluaita.org

the DUALITY study group

Elias P. Rosen¹, Stephen Bondoc², Lucía Bailón^{3,4,5}, Lidia Blay⁶, Albert Caballero⁶, Maria C. García-Guerrero⁷, Maria C. Puertas^{5,7,8}, Igor Moraes-Cardoso^{7,8,9}, Andrea Vazquez-Escobales^{3,4}, Julià Blanco^{5,7,8,10}, Beatriz Mothe^{3,4,5,7,8,10}, Angela DM Kashuba¹, Jacob D. Estes^{2,11}, Javier Martinez-Picado^{5,7,8,10,12}, Jose Molto^{3,4,5,8}, Joan Francesc Julian⁶, Yovaninna Alarcón-Soto⁴, Susana Benet^{3,4}, Cristina Miranda⁴, Aroa Nieto⁴, Roger Paredes^{3,4,7,8,10}, Angel Rivero^{3,4}, Sofia Sabato^{3,4}, Ester Aparicio⁷, Christian Brander^{5,7,12}, Silvia Marfil⁷, Alex Olvera⁷, Edwards Pradenas⁷, Victor Urrea⁷, Yury Desyaterik¹ & Nicole White¹